Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Donors do the amazing by helping create life-saving medicines for patients. A program from CSL Plasma helps connect the two.
A Medical Affairs leader reflects on her roles as a granddaughter, daughter and doctor and shares how CSL is working to impro…
Learn more about this substance in your blood, which the body needs, just not too much.
As school resumes, a pediatric psychologist, a nurse and a mom offer advice on talking with school staff about health conditi…
Get 3 tips from an immunologist for how to manage fall and winter 2022.
New podcast episode explores connection to fly fishing organization that helps disabled veterans and wounded, injured and ill…
How can a parent be an advocate for a child in pain due to a condition like sickle cell disease? We asked a doctor, the mothe…
It's the right time to work for consensus to improve the care of rare disease patients, CSL Behring leaders say.
Eyo, who received an Uplifting Athletes grant to research SLC6A1, gives an update on his work and gives credit to the mom of …
Americas
Asia Pacific
Middle East
Europe
